RELATED STUDY
Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico
Key Findings: This case study of 4 individuals and the efficacy and safety of cannabidiol as an adjunct therapy in the treatment of anxiety-related disorders finds cannabidiol (CBD) is safe and effective when combined with cognitive therapies.
Type of Study: Meta-analysis
Study Sample Size: 4
Study Result: Positive
Study Location(s): Mexico
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Endocannabinoid (unspecified)
Phytocannabinoid Source: Isolate
Chemotype: Chemotype III
Terpenes Studied: ß-Caryophyllene, Borneol
Receptors Studied: CB1, CB2, GPCR 3, GPCR 6, GPCR 18, GPCR 55, TRPA1, TRPV1, TRPV2, TRPV4, PPAR - Gamma, GPCR
Ligands Studied: GABA, Glutamate, Serotonin
DOSING DETAILS 
Study Dosing Objective: Effective Dose, Safety Profile
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion)
Cannabinoid Ratio: (CBD) 0 
Dosing Regimen: CBD (20–80 mg/day)
Maximum Dose: 80 mg/day
Link to study
